

Dr. Joël Doré, MaaT Pharma's co-founder, received awards for his work

Hello!

Recent events and awards have made us so proud that we decided to share it with you!

Let me give you a quick reminder on who we are, what we do, and strive to do!

Created in the end of December 2014, MaaT Pharma, a microbiome specialized biotech, aims to be the leader in Microbiotherapy.

We work on reconstructing the entire gut ecosystem using autologous and allogenic Fecal Microbiota Transfer, and we are targeting severe iatrogenic dysbiosis (intestinal microbiota imbalance). Since its inception, MaaT Pharma benefited from the work on 30+years of microbiota research led by Inra (one of MaaT Pharma investors as well as a world leader in research on human Gut Microbiota) and Dr. Joël Doré, a world expert on intestinal microbiota who also happens to be one of our cofounders.

MaaT Pharma in 2017




St European proprietary GMP versatile platform focusing in hematology-oncology and infectious diseases operating since Nov 2016











Strategic **partnership** with Biocodex to develop an oral form

Our combination of unprecedented scientific and medical expertise (Dr. Joël Doré and Pr. Mohamad Mohty) and our unique proprietary technology has allowed us to move fast, and today we are one of the few companies in the clinical phase II development in the field of microbiota. MaaT Pharma is currently developing innovative treatments for unmet medical needs in hematology-oncology, infectious diseases, and immune diseases such as GvHD.

Our end game: leverage the microbiota's capacity to successfully treat patients with serious illnesses.

Dr. Joël Doré has received several awards for his outstanding work

Today, we are extremely proud to announce that Dr. Doré, who has been by our side since the very beginning, has received two awards to honor his work.



On **November 20th, 2017**, he received the **Inra Lifetime Achievement Award** during the 12th INRA Awards ceremony. Each year, the Inra Awards honor the creativity, talent, and commitment of INRA researchers, engineers, and technicians. As stated by Dr. Doré, "In the years to come, (my) goal is to conduct a more detailed exploration of the microbiota and to develop tools for personalizing preventive nutrition and medical treatments."



Autism and many other chronic clinical indications have in common an altered symbiosis characterized by severely disrupted microbiome facing a low grade to acute inflammatory tone. Current therapies only tackle symptoms while microbiotherapy, as developed by MaaT Pharma, could open the perspective to fully restore symbiosis, leverage microbiota's capacity to mitigate inflammation and thereby provide long term remission. said Joël Doré.



Recently, researchers have published new evidence regarding the role of an altered gut microbiota in gastrointestinal and metabolic disorders, NASH/NAFLD cases, and in autism spectrum disorder. These findings give a glimpse of the tremendous potential microbiota holds when it comes to maintaining health and treating diseases.

MaaT Pharma on the road



December 9-12, ASH 2017: MaaT Pharma presented a 'first in patient' data at ASH 2017 in Atlanta on Autologous Fecal Microbiota Transfer and Restoration of Microbiota diversity. We completed our first clinical study proving that MaaT Pharma's Autologous Fecal Microbiota Transfer induced a 90% recovery of gut microbiome diversity. These promising results could open new avenues for treating several conditions in the hematology-oncology field.

What's coming up?

MaaT Pharma will attend the following events 2018 promises





January, 2018



2018 promises to be as excited as 2017 so stay tuned for updates on our development and on our clinical trials!

If you have any questions regarding MaaT Pharma, do not hesitate to contact me.

Best regards,

Hervé Affagard CEO and co-founder of MaaT Pharma